Wells Fargo & Company MN Acquires 20,950 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

Wells Fargo & Company MN boosted its holdings in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 51.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 62,021 shares of the company’s stock after purchasing an additional 20,950 shares during the period. Wells Fargo & Company MN’s holdings in Sana Biotechnology were worth $101,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Barclays PLC lifted its holdings in Sana Biotechnology by 126.6% during the third quarter. Barclays PLC now owns 318,910 shares of the company’s stock worth $1,325,000 after acquiring an additional 178,179 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Sana Biotechnology in the 4th quarter valued at about $239,000. Charles Schwab Investment Management Inc. raised its stake in shares of Sana Biotechnology by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,056,512 shares of the company’s stock valued at $1,722,000 after purchasing an additional 8,666 shares during the period. Geode Capital Management LLC raised its stake in shares of Sana Biotechnology by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 3,193,081 shares of the company’s stock valued at $5,206,000 after purchasing an additional 26,601 shares during the period. Finally, Corient Private Wealth LLC raised its stake in shares of Sana Biotechnology by 161.7% in the 4th quarter. Corient Private Wealth LLC now owns 1,182,699 shares of the company’s stock valued at $1,928,000 after purchasing an additional 730,699 shares during the period. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Stock Performance

NASDAQ:SANA opened at $1.81 on Monday. The stock’s 50-day simple moving average is $1.93 and its 200 day simple moving average is $2.47. The company has a market cap of $408.11 million, a P/E ratio of -1.29 and a beta of 1.75. Sana Biotechnology, Inc. has a 52-week low of $1.26 and a 52-week high of $9.49.

Sana Biotechnology (NASDAQ:SANA) last released its earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02. As a group, equities analysts predict that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Sana Biotechnology in a research note on Thursday, April 24th. Citizens Jmp raised Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a research note on Tuesday, March 18th. Finally, Jefferies Financial Group assumed coverage on Sana Biotechnology in a research note on Friday, March 14th. They issued a “buy” rating and a $7.00 price target on the stock. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.80.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.